Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Phospholipase A2 Inhibitors

Known as: A2 Antagonists, Phospholipase, Phospholipase A2 Antagonists, Antagonists, Phospholipase A2 
Compounds that inhibit or block the activity of a PHOSPHOLIPASE A2 enzyme.
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (7)

AX 059PF-5212372darapladibecopladib
Expand
In Bloodaspects of radiation effectschemical synthesisstandards characteristics

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Phospholipase A2 inhibitors protect against prion and Aβ mediated synapse degeneration
BackgroundAn early event in the neuropathology of prion and Alzheimer's diseases is the loss of synapses and a corresponding… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Up-regulation of the expressions of phospholipase A2 inhibitors in the liver of a venomous snake by its own venom phospholipase A2.
Venomous snakes such as Gloydius brevicaudus have three distinct types of phospholipase A(2) inhibitors (PLIalpha, PLIbeta, and… Expand
Is this relevant?
2009
2009
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic
Phase II results of the trials of two phospholipase A2 inhibitors which may be of value in the treatment of atherosclerosis and… Expand
Is this relevant?
2006
2006
Secreted phospholipase A2 inhibitors are also potent blockers of binding to the M-type receptor.
Mammalian secreted phospholipases A(2) (sPLA(2)s) constitute a family of structurally related enzymes that are likely to play… Expand
  • figure 2
  • figure 5
  • table 2
  • table 3
Is this relevant?
2005
2005
Secretory phospholipase A2 inhibitors and calmodulin antagonists as inhibitors of cytosolic phospholipase A2
Human cytosolic phospholipase A2 (cPLA2, 85 kDa) appears to be pharmacologically distinct from human secretory phospholipase A2… Expand
  • table 1
Is this relevant?
2004
2004
Phospholipase A2 Inhibitors or Platelet-activating Factor Antagonists Prevent Prion Replication*
A key feature of prion diseases is the conversion of the cellular prion protein (PrPC) into disease-related isoforms (PrPSc), the… Expand
Is this relevant?
1999
1999
Phospholipase A2 inhibitors and leukotriene synthesis inhibitors block TNF-induced NF-kappaB activation.
Tumour necrosis factor (TNF) is a key regulator of inflammation and immunity. The cellular effects exerted by TNF depend, apart… Expand
Is this relevant?
1994
1994
Rational modification of human synovial fluid phospholipase A2 inhibitors.
Mammalian nonpancreatic secretory phospholipase A2 (PLAz) splits the 2-acyl bond in 1,2-diacylpho~phatide.~ This enzyme has been… Expand
Is this relevant?
1991
1991
Group II phospholipase A2 inhibitors suppressed lysophosphatidylserine-dependent degranulation of rat peritoneal mast cells.
Rat peritoneal mast cells were sensitized with IgE and challenged with the specific antigen in the presence of… Expand
Is this relevant?
1989
1989
Superoxide generation is inhibited by phospholipase A2 inhibitors. Role for phospholipase A2 in the activation of the NADPH oxidase.
The stimulation of O2.- generation by phorbol 12-myristate 13-acetate (PMA) in human neutrophil-derived cytoplasts was inhibited… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE